Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.
Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

June 6th 2025

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.
Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

June 5th 2025

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.
An International Search for Lung Cancer Treatment Leads to Double Lung Transplant

June 4th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.
Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC

June 4th 2025

Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC
Significant OS Benefit Observed With NAT Nivolumab/Chemo in Resectable NSCLC

June 3rd 2025

Video Series
Video Interviews
Podcasts
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN, discusses how LungTalk, a health communication and decision support tool, may spread awareness and knowledge surrounding lung cancer screening.
Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study
OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC

More News